Top Markets
Coin of the day
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Κατάταξη σε μετοχές #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Τιμή μετοχής
$0.1502
Τελευταίος συγχρονισμός: 2024-11-04
Κεφαλαιοποίηση
$6.43M
Αλλαγή (1 ημέρα)
-5.45%
Αλλαγή (1 έτος)
0.00%
Χώρα
US
Εμπόριο Renalytix Plc (RNLX)

Κατηγορία

Κέρδη για την Renalytix Plc (RNLX)
Κέρδη τον Sep 2024 TTM: $-28.67M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Renalytix Plc, τα τρέχοντα κέρδη της εταιρείας είναι $-28.67M. Το 2023, η εταιρεία παρουσίασε κέρδη $-46.22M, μείωση σε σύγκριση με των κερδών του 2022 που ήταν $-45.25M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Renalytix Plc από 2018 έως 2026
Κέρδη στο τέλος κάθε έτους
Έτος Κέρδη Αλλαγή
2026 (TTM) $-28.67M -14.29%
2024 $-33.45M -27.63%
2023 $-46.22M 2.14%
2022 $-45.25M 26.44%
2021 $-35.79M 237.30%
2020 $-10.61M 62.78%
2019 $-6.52M 1,459.33%
2018 $-418.00K 0.00%
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
Εταιρεία Κέρδη Διαφορά Κερδών Χώρα
$2.04B -7,225.67%
US
$222.34M -875.49%
AU
$295.53M -1,130.77%
US
$-259.89M 806.47%
US
- -
US